A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Oh, D.-Y., Chen, L.-T., He, A.R., Okusaka, T., Qin, S., Chin, S., Rokutanda, N., Uchinda, H., Vogel, A., Valle, J.W., Kim, H.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
831TiP - A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Oh, D.-Y., Chen, L.-T., He, A.R., Okusaka, T., Qin, S., Chin, S., Rokutanda, N., Uchinda, H., Vogel, A., Valle, J.W., Kim, H.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
831TiPA phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Oh, D-Y, Chen, L-T, He, A R, Okusaka, T, Qin, S, Chin, S, Rokutanda, N, Uchinda, H, Vogel, A, Valle, J W, Kim, H
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article